Home
INVA

INVA

Innoviva Inc.

as of 12-04-2025 3:45pm EST

$20.77

$0.09

-0.43%

Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.

#24 in Best Pharma Stocks

Chart Type:

Time Range:

Founded:	1996	Country:	United States
Employees:	N/A	City:	BURLINGAME
Market Cap:	1.6B	IPO Year:	2004
Target Price:	$36.60	AVG Volume (30 days):	929.9K
Analyst Decision:	Buy	Number of Analysts:	5
Dividend Yield:	N/A	Dividend Payout Frequency:	N/A
EPS:	1.52	EPS Growth:	53.96
52 Week Low/High:	$16.52 - $22.76	Next Earning Date:	11-05-2025
Revenue:	$388,521,000	Revenue Growth:	10.14%
Revenue Growth (this year):	13.23%	Revenue Growth (next year):	8.62%

AI-Powered INVA Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold

Model Accuracy: 74.50%

74.50%

Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

View Full INVA Forecast & Prediction with Hourly Data

Compare INVA vs Leading Stocks

See how INVA stacks up against similar companies in the market

Share on Social Networks:

Tools & Resources

Enhance your trading experience with our free tools

Free INVA Stock Widget

Embed our interactive stock ticker widget on your website for real-time updates.

Free Tool

Stock Alerts on Telegram

Get instant notifications, market insights, and expert analysis delivered to your phone.

Live Updates

Disclaimer

The information presented on this page, "INVA Innoviva Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.